Caplin Point Laboratories Ord B share price
You have to be logged in to add this to Watchlist.- ₹2,015.50(2.92%)March 21, 2025 15:29:27 PM IST
- NSE
- BSE
- Vol : 1.10M (NSE + BSE)Last 20 day avg : 179.49 K
Caplin Point Laboratories Ord B is trading 2.92% upper at Rs 2,015.50 as compared to its last closing price. Caplin Point Laboratories Ord B has been trading in the price range of 2,047.05 & 1,888.50. Caplin Point Laboratories Ord B has given -20.09% in this year & 8.49% in the last 5 days. Caplin Point Laboratories Ord B has TTM P/E ratio 36.87 as compared to the sector P/E of 29.43.There are 2 analysts who have initiated coverage on Caplin Point Laboratories Ord B. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 138.96 Crores in its last quarter.Listed peers of Caplin Point Laboratories Ord B include Eris Lifesciences (1.75%), Alembic Pharmaceuticals (13.62%), Caplin Point Laboratories Ord B (2.92%).The Mutual Fund holding in Caplin Point Laboratories Ord B was at 1.86% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Caplin Point Laboratories Ord B was at 4.84% in 31 Dec 2024. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Mar 24, 2025, 01:07 AM UTC
- Dividend YieldLower than industry0.13Annual dividends as a percentage of the stock price.
- P/BHigher than historical values6.55The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values29.59Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility0.88Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityLower than industry0.00The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in December quarter by 13.19% from Rs 492.96 crore to Rs 435.50 crore, year-on-year
- The company has grown its December quarter profit by 18.57% from Rs 117.20 crore to Rs 138.96 crore, year-on-year
- The debt to equity of the company is lower than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,035.85
- R2
- 2,248.95
- R3
- 2,450.85
- S1
- 1,620.85
- S2
- 1,418.95
- S3
- 1,205.85
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences | Bullish | 1,390.90 | 1.75 | 18,934.22 | 48.08 | 7.32 | 0.53 | 26.74 |
| Alembic Pharmaceuticals | Neutral | 947.75 | 13.62 | 18,601.78 | 30.49 | 3.89 | 1.15 | 1.31 |
| Caplin Point Laboratories Ord B | Neutral | 2,015.50 | 2.92 | 15,320.16 | 33.32 | 6.55 | 0.25 | 0.04 |
| Natco Pharma | Neutral | 829.35 | 0.40 | 14,854.47 | 10.71 | 2.54 | 0.72 | 0.09 |
| Jubilant Pharmova | Moderately Bearish | 902.85 | 0.43 | 14,380.70 | 96.18 | 2.63 | 0.55 | 61.92 |
- Promoter(s) holds a high stake in the company at 70.56%
Promoter(s) have decreased the stake in the company in last 12 months- FIIs are invested in this company
- FIIs holding has increased by 1.15 percentage points from previous quarter
- Mutual Funds holding has increased by 0.24 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-07 | Quarterly Results |
| 2024-11-07 | Quarterly Results |
| 2024-08-07 | Quarterly Results & Final Dividend |
| 2024-05-16 | Audited Results & Interim Dividend |
| 2024-02-09 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE475E01026
- BSE Code524742
- NSE CodeCAPLIPOINT
Caplin Point Laboratories Ord B is trading at 2015.50 as on Fri Mar 21 2025 09:59:27. This is 2.92% upper as compared to its previous closing price of 1958.30.
The market capitalization of Caplin Point Laboratories Ord B is 15320.16 Cr as on Fri Mar 21 2025 09:59:27.
The average broker rating on Caplin Point Laboratories Ord B is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Caplin Point Laboratories Ord B is 2636.00 whereas the 52 wk low is 1221.00
Caplin Point Laboratories Ord B can be analyzed on the following key metrics -
- TTM P/E: 36.87
- Sector P/E: 29.43
- Dividend Yield: 0.13%
- D/E ratio: -
Caplin Point Laboratories Ord B reported a net profit of 457.09 Cr in 2024.
The Mutual Fund Shareholding was 1.86% at the end of 31 Dec 2024.